| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/24/2011 | CA2401604C Method of treating cancer with anti-neurotrophin agents |
| 05/24/2011 | CA2393710C Caspase inhibitors and uses thereof |
| 05/24/2011 | CA2384378C Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 05/24/2011 | CA2345277C Methods for isolation, quantification, characterization and modulation of antigen-specific t cells |
| 05/24/2011 | CA2323072C Gfr.alpha.3 and its uses |
| 05/19/2011 | WO2011060217A1 Spiropiperidine compounds as orl-1 receptor antagonists |
| 05/19/2011 | WO2011060035A1 Spiropiperidine compounds as orl-1 receptor antagonists |
| 05/19/2011 | WO2011060026A1 Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| 05/19/2011 | WO2011059148A1 Composition for counteracting smoking toxicity |
| 05/19/2011 | WO2011059048A1 Novel amide derivative |
| 05/19/2011 | WO2011059021A1 8-azabicyclo[3.2.1]octane-8-carboxamide derivative |
| 05/19/2011 | WO2011058933A1 Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing same |
| 05/19/2011 | WO2011058932A1 N-benzyl amide derivative and pharmaceutical composition containing same |
| 05/19/2011 | WO2011058766A1 Aryl carboxamide derivatives as ttx-s blockers |
| 05/19/2011 | WO2011058763A1 Aminothiazine or aminooxazine derivative having amino linker |
| 05/19/2011 | WO2011058478A1 Substituted triazolopyrimidines as pde8 inhibitors |
| 05/19/2011 | WO2011058262A1 Xenon-based inhalable drug for treating or preventing induced dyskinesia |
| 05/19/2011 | WO2011058113A1 Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058110A1 Quinoline and quinoxaline derivatives as kinase inhibitors |
| 05/19/2011 | WO2011058108A1 Quinoline and quinoxaline derivatives as kinase inhibitors |
| 05/19/2011 | WO2011057973A1 Oxazoline derivatives for treatment of cns disorders |
| 05/19/2011 | WO2011057471A1 Methods and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine d2l receptor |
| 05/19/2011 | WO2011057382A1 Spirocyclic piperidine derivatives useful as renin inhibitors |
| 05/19/2011 | WO2011057340A1 Process for plant bioactive enrichment |
| 05/19/2011 | WO2011029775A8 [1,2,4]triazolo [1,5-c]pyrimidine derivatives as hsp90 modulators |
| 05/19/2011 | WO2011011376A3 Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine |
| 05/19/2011 | WO2011009097A9 Methods for treating schizophrenia |
| 05/19/2011 | WO2011008585A3 Methods and compositions for protecting and treating neuroinjury |
| 05/19/2011 | WO2011002168A3 Use of novel lactobacillus helveticus or a culture thereof for preventing or treating dementia or cognitive dysfunction |
| 05/19/2011 | WO2010147938A3 Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
| 05/19/2011 | WO2010138392A3 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin |
| 05/19/2011 | WO2010136000A4 Steroide anionic compounds, method of their production, usage and pharmaceutical preparation involving them |
| 05/19/2011 | WO2010130799A3 Method for impregnation with supercritical co2 |
| 05/19/2011 | US20110118357 Process for preparing o-desmethylvenlafaxine |
| 05/19/2011 | US20110118355 Treatment of migraine headaches using antiestrogens |
| 05/19/2011 | US20110118340 Delivery of rnai constructs to oligodendrocytes |
| 05/19/2011 | US20110118338 Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
| 05/19/2011 | US20110118325 Rel inhibitors and methods of use thereof |
| 05/19/2011 | US20110118324 Method and composition for treating multiple sclerosis (variants) |
| 05/19/2011 | US20110118323 Macrocyclic compounds and methods of treatment |
| 05/19/2011 | US20110118317 Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
| 05/19/2011 | US20110118313 Identification of a molecular signature for antipsychotics and serms |
| 05/19/2011 | US20110118312 Benzylpiperizine compound |
| 05/19/2011 | US20110118310 Treatment Using D-Threo Methylphenidate |
| 05/19/2011 | US20110118305 Compounds |
| 05/19/2011 | US20110118304 Method for treating over-eating disorders |
| 05/19/2011 | US20110118301 Amino-Aza-Adamantane Derivatives and Methods of Use |
| 05/19/2011 | US20110118299 Treatment of mci and alzheimer's disease |
| 05/19/2011 | US20110118294 Intranasal Opioid Compositions |
| 05/19/2011 | US20110118289 6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands |
| 05/19/2011 | US20110118287 Bicycloheteroaryl Compounds As P2X7 Modulators and Uses Thereof |
| 05/19/2011 | US20110118275 OXAZOLO[4,5-c]PYRIDINE SUBSTITUTED PYRAZINE |
| 05/19/2011 | US20110118273 Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| 05/19/2011 | US20110118270 Heterocyclic derivatives that are used in the treatment of neurodegenerative diseases |
| 05/19/2011 | US20110118268 Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators |
| 05/19/2011 | US20110118264 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof |
| 05/19/2011 | US20110118263 Benzothiophene alkanol piperazine derivatives and their use as antidepressant |
| 05/19/2011 | US20110118261 Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists |
| 05/19/2011 | US20110118259 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 05/19/2011 | US20110118257 Novel kinase modulators |
| 05/19/2011 | US20110118256 Imidazo [1,2-a] pyridin-3-yl-acetic acid hydrazides, processes, uses and compositions |
| 05/19/2011 | US20110118253 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors |
| 05/19/2011 | US20110118251 Spiropiperidine compounds as orl-1 receptor antagonists |
| 05/19/2011 | US20110118250 Beta-secretase modulators and methods of use |
| 05/19/2011 | US20110118248 Heteroaryl sulfonamides and CCR2/CCR9 |
| 05/19/2011 | US20110118247 2-Methyl-5-Imino-Benzo[D][1,3]Oxazin[5-B]Pyrazole Compound, Preparation and Use Thereof |
| 05/19/2011 | US20110118246 Novel Compounds |
| 05/19/2011 | US20110118242 3,7-diamino-10h-phinothiazine salts and their use |
| 05/19/2011 | US20110118239 Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4]nonane and novel salt forms of the racemate and enantiomers |
| 05/19/2011 | US20110118236 Heterocyclic compound |
| 05/19/2011 | US20110118234 Urea Compounds as Gamma Secretase Modulators |
| 05/19/2011 | US20110118232 Pyrimidine compounds and use thereof |
| 05/19/2011 | US20110118231 Modulators of 5-ht receptors and methods of use thereof |
| 05/19/2011 | US20110118201 Glutathione production enhancer, prophylactic/therapeutic agent for diseases caused by glutathione deficiency, and food, beverage and feed |
| 05/19/2011 | US20110118189 Novel formulations for treatment of migraine |
| 05/19/2011 | US20110118172 Metastin derivative and use thereof |
| 05/19/2011 | US20110117215 Microsatellite Markers of Schizophrenia |
| 05/19/2011 | US20110117214 Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| 05/19/2011 | US20110117200 Rasagiline mesylate particles and process for the preparation thereof |
| 05/19/2011 | US20110117196 Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects |
| 05/19/2011 | US20110117192 Carbidopa/lipodopa gastroretentive drug delivery |
| 05/19/2011 | US20110117186 Intravenous infusion of curcumin and a calcium channel blocker |
| 05/19/2011 | US20110117184 Compositions for mucosal delivery of agents |
| 05/19/2011 | US20110117136 Dehydroepiandrosterone production promoter and use thereof |
| 05/19/2011 | US20110117121 Compositions for treatment and inhibition of pain |
| 05/19/2011 | US20110117115 Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
| 05/19/2011 | US20110117112 Sodium channel protein type iii alpha-subunit splice variant |
| 05/19/2011 | US20110117100 Compositions and methods for diagnosis, stratification and treatment of amyloidogenic diseases |
| 05/19/2011 | US20110117095 Growth factor htter36 |
| 05/19/2011 | US20110117094 Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury |
| 05/19/2011 | US20110117093 Antibodies that immunospecifically bind to b lymphocyte stimulator protein |
| 05/19/2011 | US20110117092 Compositions and methods for inhibiting g-csfr |
| 05/19/2011 | US20110117073 Protein Kinase Conjugates and Inhibitors |
| 05/19/2011 | US20110117070 Compositions and methods for treating headache |
| 05/19/2011 | US20110117069 Method for activating regulatory t-cells |
| 05/19/2011 | US20110117050 Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen |
| 05/19/2011 | US20110117022 Method of using and establishing an absorption rate level and a neuron firing level |
| 05/19/2011 | US20110117021 Fully human anti-vap-1 monoclonal antibodies |
| 05/19/2011 | US20110117015 Diagnostic Agents Selective Against Metalloproteases |
| 05/19/2011 | CA2796161A1 Spiropiperidine compounds as orl-1 receptor antagonists |